XML 39 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information
 12 Months Ended
Jun. 30, 2020
Segment Reporting [Abstract]  
Segment Information

The Company’s chief operating decision maker (the “CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.

 

Aytu manages the Company and aggregated our operational and financial information in accordance with two reportable segments: Aytu BioScience and Aytu Consumer Health. The Aytu BioScience segment consists of the Company’s prescription products. The Aytu Consumer Health segment contains the Company’s consumer healthcare products, which was the result of the Innovus Merger. Select financial information for these segments is as follows:

 

    As of June 30,  
    2020     2019  
 Consolidated revenue:            
 Aytu BioScience   $ 17,249,000     $ 7,320,000  
 Aytu Consumer Health     10,383,000       -  
 Consolidated revenue   $  27,632,000     $  7,320,000  
                 
                 
 Consolidated net loss:                
 Aytu BioScience   $  (10,464,000 )   $  (27,132,000 )
 Aytu Consumer Health     (3,157,000 )     -  
 Consolidated net loss   $  (13,621,000 )   $  (27,132,000 )
                 
                 
 Total assets:                
 Aytu BioScience   $ 126,267,000     $ 34,721,000  
 Aytu Consumer Health     26,569,000       -  
 Total assets   $ 152,836,000     $ 34,721,000  

 

    As of June 30,  
    2020     2019  
Goodwill            
Aytu BioScience   $ 19,453,000     $  –  
Aytu Consumer Health     8,637,000       –  
Consolidated Goodwill   $ 28,090,000     $  –